'The data being presented at this year's WCN meeting aid in expanding our knowledge of migraine so we can continue to better understand this treatment option,' said
Featured data include pooled analyses of different trials examining outcomes related to efficacy and safety, quality of life and disability in patients with different migraine frequency, patients who have inadequate response to previous preventive treatments, patients within different ethnic subgroups and patients with medication overuse headache.
Addressing healthcare disparities within migraine treatment is a key area of focus. A recent review of literature published in Neurology shows how disparities in race, ethnicity, socioeconomic status, geography, and other factors contribute to the inequitable treatment of those diagnosed with headache disorders.1
Teva will host an online symposium, 'Envisioning a More Inclusive, Diverse and Equitable Global Migraine Landscape: Are We Making Progress?' on
The symposium is designed to address the following objectives:
Build awareness of healthcare disparities as a major public health issue by highlighting social determinants of health and defining concepts and terms relevant to understanding health disparities and diversity
Critique the state of diversity in migraine clinical studies, review barriers to recruitment, and discuss the need for more inclusive and diverse studies
Examine inclusivity of anti-CGRP mAb clinical studies specifically, and review latest data from diverse sub-populations, e.g. different ethnicities, migraine characteristics and comorbidities
'To help ensure migraine patients are receiving the care they need, it's important to understand all factors that contribute to a person's health and disease state. Both demographic and non demographic factors are important to consider when treating our patients. We are excited to lead this conversation to help build awareness around health disparities to ensure more equity in neurology treatment,' said
The full set of abstracts approved by the congress scientific committee and sponsored by Teva include:
De novo
'Fremanezumab Improves Quality of Life in Patients With Higher- and Lower-Frequency Chronic Migraine'
'Fremanezumab Improves Quality of Life in Patients With High- and Moderate-Frequency Episodic Migraine'
'Efficacy and Improvements in Disability and Quality-of-Life With Fremanezumab Over 6 Months in Migraine Patients With Inadequate Response by Multiple Prior Preventive Treatment Classes'
'Reversion From Medication Overuse With Fremanezumab Treatment in Patients With Inadequate Response to Multiple Migraine Preventive Medication Classes'
'Progressive Improvements in Efficacy and Disability With Fremanezumab in Patients With Medication Overuse And Inadequate Response to Multiple Migraine Preventive Medication Classes'
'Efficacy Of Fremanezumab in Patients With Chronic and Episodic Migraine Stratified by Migraine Frequency'
'Efficacy And Tolerability of Fremanezumab for Migraine Preventive Treatment in Korean Patients With Chronic or Episodic Migraine'
'Pooled Analysis of Safety and Efficacy of Fremanezumab in Different Racial and Ethnic Subgroups of Patients With Migraine'
About Teva
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as 'should,' 'expect,' 'anticipate,' 'estimate,' 'target,' 'may,' 'project,' 'guidance,' 'intend,' 'plan,' 'believe' and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to the commercial success of AJOVY; our ability to successfully compete in the marketplace, including our ability to develop and commercialize biopharmaceutical products, competition for our specialty products, including AUSTEDO, AJOVY and COPAXONE; our ability to achieve expected results from investments in our product pipeline, our ability to develop and commercialize additional pharmaceutical products, and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantial indebtedness; our business and operations in general, including uncertainty regarding the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general, our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith, costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID-19 pandemic; compliance, regulatory and litigation matters, including failure to comply with complex legal and regulatory environments; other financial and economic risks; and other factors discussed in our Annual Report on Form 10-K for the year ended
1 Kiarashi J, VanderPluym J, Szperka CL, et al. Factors associated with, and mitigation strategies for, healthcare disparities faced by patients with headache disorders. Neurology. Published online
Contact:
IR
T: (215) 591-8912
(C) 2021 Electronic News Publishing, source